Skip to main content

Table 1 Baseline characteristics of the 20 trials used in the meta-analysis

From: Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis

Author Year Country No. of patients Stage Assay Follow-up (months) NOS score
Andersen [20] 2011 Norway 335 I–III IHC 86 8
Coelho [22] 2014 Portugal 92 I–IV RT-PCR NA 6
Daly [27] 2014 USA 197 NA ELISA 60 7
Huang [28] 2012 China 59 I–III IHC NA 6
Jiang [29] 2015 China 50 I–III IHC NA 5
Li [30] 2015 China 88 I–IV ELISA NA 5
Liu [31] 2010 China 50 I–IV IHC 60 7
Liu [32] 2014 China 40 I–IV ELISA 30 6
Massabeau [33] 2008 France 78 III IHC NA 5
Park [34] 2007 South Korea 110 I–IV ELISA 22.1 8
Park [35] 2009 South Korea 101 I–II ELISA NA 5
Sasaki [36] 2012 Japan 110 I–IV RT-PCR 60 8
Takanami [37] 2004 Japan 77 I–III RT-PCR、IHC 60 7
Tanaka [38] 2002 Japan 236 I–III IHC 60 8
Wan [39] 2008 China 98 I–IV ELISA 12 5
Wang [40] 2015 China 114 I–IV IHC NA 7
Xiao [41] 2010 China 41 I–III IHC NA 7
Xing [42] 2003 China 52 I–III RT-PCR NA 7
Yuan [43] 2007 China 46 NA IHC NA 5
Zhang [44] 2008 China 37 I–III IHC NA 7
  1. NA not available, NOS Newcastle–Ottawa Scale, RT-PCR real-time polymerase chain reaction, IHC immunohistochemistry, ELISA enzyme-linked immunosorbent assay